Parkinson’s Disease Psychosis Treatment Market 2034: Clinical Trials, Medication, Pipeline Therapies, EMA, PDMA, FDA Approvals and Companies by DelveInsight
(Albany, USA) DelveInsight’s “Parkinson’s Disease Psychosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Parkinson’s Disease Psychosis, historical and forecasted epidemiology as well as the Parkinson’s Disease Psychosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Parkinson’s Disease Psychosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Parkinson’s Disease Psychosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Parkinson’s Disease Psychosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Parkinson’s Disease Psychosis market.
Request for a Free Sample Report @ Parkinson’s Disease Psychosis Market Forecast
Some facts of the Parkinson’s Disease Psychosis Market Report are:
- According to DelveInsight, Parkinson’s Disease Psychosis market size is expected to grow at a decent CAGR by 2034.
- The Parkinson’s Disease Psychosis market size of in the 7MM was approximately USD 665 million in 2023.
- Parkinson’s Disease Psychosis companies working in the treatment market are Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences, and others are developing therapies for the Parkinson’s Disease Psychosis treatment
- Emerging Parkinson’s Disease Psychosis therapies in the different phases of clinical trials are- Iloperidone, Istradefylline, SAGE-718, ATH-1017, NYX-458, pimavanserin tartrate, AGB101, and others are expected to have a significant impact on the Parkinson’s Disease Psychosis market in the coming years.
- In October 2024, Adaptive Research, an organization focused on broadening access to clinical trials, has announced its involvement in an innovative decentralized Parkinson’s disease study sponsored by PhotoPharmics Inc. The California Movement Disorders Center, a member of Adaptive Research’s network, will act as a site for the LIGHT-PD trial, which evaluates the effectiveness of Celeste® Specialized Phototherapy in managing Parkinson’s symptoms.
- In September 2024, AbbVie’s newly acquired Parkinson’s disease treatment candidate, tavapadon, demonstrated a significant reduction in disease burden during a Phase III trial. The TEMPO-1 Phase III study (NCT04201093) assessed tavapadon at daily doses of 5mg and 15mg. The trial achieved its primary endpoint, with both dosing groups showing superior improvements compared to placebo at week 26, based on a combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
Parkinson’s Disease Psychosis Overview
Parkinson’s Disease Psychosis (PDP) is a non-motor complication of Parkinson’s disease (PD), characterized by hallucinations, delusions, or other psychotic symptoms. It typically emerges in the later stages of Parkinson’s Disease, significantly impacting the patient’s quality of life and placing a burden on caregivers.
The exact cause of Parkinson’s Disease Psychosis is multifactorial, involving the progression of Parkinson’s pathology, imbalances in neurotransmitters like dopamine and serotonin, and side effects of dopaminergic therapies used to manage motor symptoms. Risk factors include advanced age, cognitive impairment, and prolonged use of Parkinson’s Disease medications.
Symptoms of Parkinson’s Disease Psychosis vary. Hallucinations, often visual, are the most common and may involve seeing people, animals, or objects that are not present. Delusions, such as false beliefs of infidelity or paranoia, can also occur. In some cases, patients are aware of these experiences (retaining insight), while others lose this awareness over time.
Treatment focuses on reducing distress and maintaining motor symptom control. Adjusting Parkinson’s Disease medications, adding atypical antipsychotics like pimavanserin (FDA-approved for Parkinson’s Disease Psychosis), or using clozapine at low doses can help manage symptoms. Non-pharmacological strategies, such as creating a calm environment and educating caregivers, are also essential. Early diagnosis and intervention improve outcomes and reduce the risk of complications such as caregiver burnout or institutionalization.
Do you know what will be the Parkinson’s Disease Psychosis market share in 7MM by 2034 @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market
Parkinson’s Disease Psychosis Market
The Parkinson’s Disease Psychosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Parkinson’s Disease Psychosis market trends by analyzing the impact of current Parkinson’s Disease Psychosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Parkinson’s Disease Psychosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Parkinson’s Disease Psychosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Parkinson’s Disease Psychosis market in 7MM is expected to witness a major change in the study period 2020-2034.
Parkinson’s Disease Psychosis Epidemiology
The Parkinson’s Disease Psychosis epidemiology section provides insights into the historical and current Parkinson’s Disease Psychosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Parkinson’s Disease Psychosis market report also provides the diagnosed patient pool, trends, and assumptions.
Interested to know how the emerging diagnostic approaches will be contributing in increased Parkinson’s Disease Psychosis diagnosed prevalence pool? Download report @ Parkinson’s Disease Psychosis Prevalence
Parkinson’s Disease Psychosis Drugs Uptake
This section focuses on the uptake rate of the potential Parkinson’s Disease Psychosis drugs recently launched in the Parkinson’s Disease Psychosis market or expected to be launched in 2020-2034. The analysis covers the Parkinson’s Disease Psychosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Parkinson’s Disease Psychosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Parkinson’s Disease Psychosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Parkinson’s Disease Psychosis Pipeline Development Activities
The Parkinson’s Disease Psychosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Parkinson’s Disease Psychosis key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Parkinson’s Disease Psychosis market share by 2034? Click here @ Parkinson’s Disease Psychosis Drugs Market
Parkinson’s Disease Psychosis Therapeutics Assessment
Major key companies are working proactively in the Parkinson’s Disease Psychosis Therapeutics market to develop novel therapies which will drive the Parkinson’s Disease Psychosis treatment markets in the upcoming years are Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences, and others.
Do you know how new drug’s market launch will be impacting the Parkinson’s Disease Psychosis market CAGR? Download sample report @ Parkinson’s Disease Psychosis Treatment Market
Parkinson’s Disease Psychosis Report Key Insights
1. Parkinson’s Disease Psychosis Patient Population
2. Parkinson’s Disease Psychosis Market Size and Trends
3. Key Cross Competition in the Parkinson’s Disease Psychosis Market
4. Parkinson’s Disease Psychosis Market Dynamics (Key Drivers and Barriers)
5. Parkinson’s Disease Psychosis Market Opportunities
6. Parkinson’s Disease Psychosis Therapeutic Approaches
7. Parkinson’s Disease Psychosis Pipeline Analysis
8. Parkinson’s Disease Psychosis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Parkinson’s Disease Psychosis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Parkinson’s Disease Psychosis Competitive Intelligence Analysis
4. Parkinson’s Disease Psychosis Market Overview at a Glance
5. Parkinson’s Disease Psychosis Disease Background and Overview
6. Parkinson’s Disease Psychosis Patient Journey
7. Parkinson’s Disease Psychosis Epidemiology and Patient Population
8. Parkinson’s Disease Psychosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Parkinson’s Disease Psychosis Unmet Needs
10. Key Endpoints of Parkinson’s Disease Psychosis Treatment
11. Parkinson’s Disease Psychosis Marketed Products
12. Parkinson’s Disease Psychosis Emerging Therapies
13. Parkinson’s Disease Psychosis Seven Major Market Analysis
14. Attribute Analysis
15. Parkinson’s Disease Psychosis Market Outlook (7 major markets)
16. Parkinson’s Disease Psychosis Access and Reimbursement Overview
17. KOL Views on the Parkinson’s Disease Psychosis Market
18. Parkinson’s Disease Psychosis Market Drivers
19. Parkinson’s Disease Psychosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
